Vanda Pharmaceuticals Inc - Company Profile
Powered by 
All the data and insights you need on Vanda Pharmaceuticals Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Vanda Pharmaceuticals Inc Strategy Report
- Understand Vanda Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Vanda Pharmaceuticals Inc (Vanda) a biopharmaceutical company that develops and commercializes novel therapies for the treatment of central nervous system disorders. The company’s products include Hetlioz, a melatonin receptor agonist for the treatment of non-24-hour sleep-wake disorder; and Fanapt, a typical antipsychotic for the treatment of schizophrenia in adults. The company’s major pipeline products include Tradipitant (VLY-686), VTR-297, VQW-765, CFTR and portfolio of cystic fibrosis transmembrane conductance regulator inhibitors and activators. Vanda is headquartered in Washington, Washington DC, the US.
Headquarters
United States of America
Address
Suite 300e, 2200 Pennsylvania Ave Nw, Washington, WashingtonD.C., 20037
Website
www.vandapharma.com
Telephone
1 202 7343400
No of Employees
203
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
VNDA (NASD)
Revenue (2022)
$192.6M
-24.3%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-60%
(2022 vs 2021)
Market Cap*
$301.5M
Net Profit Margin (2022)
XYZ
-47.4%
(2022 vs 2021)
* As of and is in US$
Vanda Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| - | - |
| HETLIOZ (tasimelteon) - Non-24-Hour Sleep-Wake Disorder | Fanapt |
| Fanapt (iloperidone) - Schizophrenia | Hetlioz |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Acquisitions/Mergers/Takeovers | In December, the company announced the acquisition of the U.S. and Canadian rights to PONVORY from Actelion Pharmaceuticals Ltd. |
| 2023 | Regulatory Approval | In June, the company announced orphan drug designation for its VCA-894A. |
| 2022 | Regulatory Approval | In October, the company announced orphan drug designation status for its VPO-227. |
Competitor Comparison
| Key Parameters | Vanda Pharmaceuticals Inc | Merck & Co Inc | Pfizer Inc | Sanofi | AstraZeneca Plc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | France | United Kingdom |
| City | Washington | Kenilworth | New York | Paris | Cambridge |
| State/Province | WashingtonD.C. | New Jersey | New York | Ile-de-France | England |
| No. of Employees | 203 | 72,000 | 88,000 | 87,994 | 89,900 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Mihael H. Polymeropoulos, MD | President; Chairman; Chief Executive Officer | Executive Board | 2003 | 63 |
| Kevin Moran | Treasurer; Senior Vice President; Chief Financial Officer | Senior Management | 2020 | 39 |
| Joakim Wijkstrom | Senior Vice President; Chief Marketing Officer | Senior Management | 2019 | 57 |
| Scott Howell | Chief People Officer | Senior Management | 2019 | - |
| Tim Williams | Senior Vice President; Secretary; General Counsel | Senior Management | 2018 | 47 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward